Transdel, JMSR partner on anti-cellulite product
This article was originally published in The Rose Sheet
Executive Summary
Jan Marini Skin Research has secured one-year exclusive rights to market an anti-cellulite cosmeceutical product in the U.S. based on Transdel Pharmaceuticals' transdermal delivery technology. The San Jose, Calif., company also has obtained non-exclusive rights to promote and sell the product in dermatological markets outside the U.S. JMSR will pay Transdel royalties, according to June 17 release. Transdel's lead drug, which has completed a Phase 3 clinical trial, employs the firm's delivery technology to facilitate passage of a non-steroidal anti-inflammatory drug through the skin directly to underlying tissues with minimal systemic exposure. "We are very excited with the establishment of our relationship with JMSR and look forward to building on this relationship in order to potentially launch additional cosmeceutical products," says Transdel CFA and Acting CEO John Lomoro. Last year Transdel said it was exploring the efficacy of its delivery system in cosmeceuticals for treating varicose veins, hyperpigmentation and signs of aging, as well as cellulite, which it identified as a multibillion-dollar global opportunity (1"The Rose Sheet" April 6, 2009)